Topical cyclosporine (Restasis) cost-utility analysis

Evidence-Based Ophthalmology

Volumn 10, Issue 3, 2009, Pages 166-171

  Brown, Gary C ^a   Brown, Melissa M ^a   Brown, Heidi C ^a   Peet, Jonathan ^a   Roth, Zachary ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ARTICLE; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRY EYE; HEALTH CARE COST; HEALTH INSURANCE; HEMODIALYSIS; HUMAN; KERATOCONJUNCTIVITIS SICCA; MEDICARE; MIGRAINE; MULTICENTER STUDY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 68249135260     PISSN: 15559203     EISSN: 15559211     Source Type: Journal    
DOI: 10.1097/IEB.0b013e3181ac94fb     Document Type: Article

References (15)

1. Schiffman RM,Walt JG, JacobsenG, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412-1419. (Pubitemid 36842481)
2. Fryback DG, Dasbach EJ, Klein R, et al. The beaver dam health outcomes study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. (Pubitemid 23113445)
3. Brown GC, Brown MM. Quality-of-Life Valuation Database. Flourtown, PA: Whitemarsh Press; 2008:306.
4. Brown GC, Brown MM. Quality-of-Life Valuation Database. Flourtown, PA: Whitemarsh Press; 2008:348.
5. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.
6. OSDI (Ocular Surface Disease Index). From qthe Internet at http://www.agape1.com/ Questionnaires/Ocular%20Surface%20Disease.pdf, Accessed on: March 12, 2008.
7. Brown MM, Brown GC, Brown HC, et al. A value-based medicine comparative effectiveness and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127:146-152.
8. Barber LD, Pflugfelder SC, Tauber J, et al. Phase III Safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790-1794. (Pubitemid 41400017)
9. Center for Drug Evaluation and Research. Application 21-023. Medical Review From the Internet at http://www.fda.gov/cder/foi/nda/2003/21-023- Restasis-Medr.PDF, Accessed on: April 4, 2008, p 104.
10. Brown MM, Brown GC, Sharma S. Evidence-Based to Value-Based Medicine. Chicago: AMA Press; 2005:125-217.
11. Centers for Medicare and Medicaid Services Physician Fee Schedule Overview. Available at: http://www.cms.hhs.gov/apps/ama/license.asp?file= physicianfeesched/downloads/pe-townhall-hcpcs-level.zip, Accessed on: September 20, 2007.
12. DeLuca MJ, ed. 2007 RED BOOK, Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2007:663-915.
13. Kozma CM, Hirsch JD, Wojcik AR. Economic and quality of life impact of dry eye symptoms. Presented at the Annual Meeting of the Association for Research in Vision. April 30-May 5, 2000, Ft. Lauderdale, Fl.
14. Data on Disability and Unemployment. From the Bureau of Labor and Statistics, on the Internet at www.bls.gov, Accessed on: April 01, 2008.
15. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Health Life. From the Internet @ www.who.int/whr/2002/en/, p 108, Accessed on: May 17, 2008.